Creso Pharma

Creso Pharma is working to develop and produce safe, cannabis- and hemp- derived therapeutic products and treatments for humans and pets.

Creso Pharma is a uniquely positioned nutraceutical and medical cannabis company, emerging in what is predicted to be a US$ 385 billion industry.

Working according to Good Manufacturing Practices (GMP) standards, Creso Pharma’s pharmaceutical-grade Nutraceuticals and Medical Cannabis products are delivered with standardised dosing and formulations, and use proprietary innovative delivery technologies to enhance the bioavailability and absorption of the cannabinoid molecules.

These products are designed to create better overall health in humans and pets.

Creso Pharma’s unique cannabinoid products aim to re-establish and bolster the balance of the body’s internal endocannabinoid system, maintain homeostasis, and alleviate a wide range of symptoms for the following medical conditions: pain and anxiety disorders, metabolic disorders and inflammatory disorders.

Creso Pharma’s products will supplement unbalanced, naturally occurring endocannabinoids with cannabinoids from the cannabis plant, naturally synergising with the body’s own endocannabinoid system.

Creso Pharma’s innovative CBD fully plant-based nutraceutical products are non-psychoactive, as they contain only trace amounts of THC.

Creso Pharma’s highly experienced pharmaceutical management team and board have a strong track record of success and many years of experience in developing and commercialising a wide range of medical and therapeutic solutions, and will be instrumental in Creso Pharma achieving its ‘go to market’ strategies.

Through worldwide distribution rights and commercialisation partners, Creso Pharma is able to develop the most competitive pharmaceutical-grade Nutraceuticals and Medical Cannabis products on the market today